#EGT European Green Transition PLC – UK proposals to increase onshore wind capacity March 23, 2026 – Posted in: European Green Transition Plc (EGT)

European Green Transition plc (AIM: EGT), a company focused on acquiring, integrating and optimising revenue-generating and profitable services businesses in the critical infrastructure sector, notes the UK Government’s announcement on 18 March 2026 outlining proposals to enable farmers, schools and industrial users to install small onshore wind turbines without the need for planning permission. The proposals are designed to reduce barriers to access distributed wind energy, allowing organisations to lower energy costs and accelerate the…

#EGT European Green Transition PLC – Investor Presentation via Investor Meet Company March 16, 2026 – Posted in: European Green Transition Plc (EGT)

European Green Transition plc (AIM: EGT), a company focused on acquiring, integrating and optimising revenue-generating and profitable services businesses in the critical infrastructure sector, announces that Cathal Friel, Executive Chair, Jack Kelly, Chief Financial Officer, and David Broadbank, Managing Director of the O&M Business will provide a live presentation via Investor Meet Company on 18 March 2026, 17:00 GMT. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via…

#EGT European Green Transition PLC – Notice of General Meeting & Posting of Circular March 13, 2026 – Posted in: European Green Transition Plc (EGT)

European Green Transition plc (AIM: EGT), a company focused on acquiring, integrating and optimising revenue-generating and profitable services businesses in the critical infrastructure sector, announces that, further to its announcement on 12 March 2026, a Circular containing further details of the Placing, the Subscription and the Notice of General Meeting will be posted to Shareholders today. The Circular will also be available on the Company’s website at www.europeangreentransition.com. The General Meeting will take place at the offices of DAC…

#EGT European Green Transition PLC – Result of fundraise via placing and subscription March 12, 2026 – Posted in: European Green Transition Plc (EGT)

European Green Transition plc (AIM: EGT), a company focused on acquiring, integrating and optimising revenue-generating and profitable services businesses in the critical infrastructure sector, announces that, further to its announcement made yesterday (the “Launch Announcement”) regarding the launch of the proposed placing and subscription (the “Fundraise”), the Company has conditionally raised gross proceeds of £7.5 million in aggregate, via the placing of 64,778,653 new Ordinary Shares of 0.25 pence each (“Ordinary Shares”) by way of…

#EGT European Green Transition PLC – Proposed fundraise to raise c. £7.5 million March 11, 2026 – Posted in: European Green Transition Plc (EGT)

European Green Transition plc (AIM: EGT), a company focused on acquiring, integrating and optimising revenue-generating and profitable services businesses in the critical infrastructure sector, announces a proposed fundraise to raise gross proceeds of approximately £7.5 million before expenses by the issue of new ordinary shares of 0.25 pence each in the Company (“Ordinary Shares”) at a price of 6 pence per Ordinary Share (the “Issue Price”) via a placing and subscription (“Fundraise”). The Fundraise of…

#HVO hVIVO PLC – Trading Update January 29, 2026 – Posted in: Uncategorized

London, UK – 29 January 2026, hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, provides a trading update for the year ended 31 December 2025 (FY25). The FY25 financials in this statement remain subject to audit. Highlights • Revenue is expected to be c.£46.7 million (2024: £62.7 million), in line with expectations • Adjusted EBITDA margin is expected to be positive low single-digit* (2024:…

#HVO hVIVO PLC – >£5 million CRS contracts signed November 20, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces its German subsidiary CRS, has signed contracts worth over £5 million since September. The early-phase clinical trial service contracts have been signed with five clients, including two returning mid-sized German pharma customers reaffirming CRS’ strong reputation and long-standing relationships in Germany. These pharma partnerships, given their volume and consistency, strengthens the Group’s sales pipeline…

#EGT European Green Transition PLC – Interim Results and M&A Strategy Update September 24, 2025 – Posted in: European Green Transition Plc (EGT)

European Green Transition (AIM: EGT), a company which aims to capitalise on the opportunities created by the green energy transition in Europe, announces its unaudited results for the six months ended 30 June 2025. Highlights · Extension of the Olserum Rare Earth Elements (“REE”) project licenses in Sweden until June 2029, following the successful completion of the Olserum REE drill programme in H2 2024 which confirmed the district scale potential for REEs at Olserum · Successful…

#HVO hVIVO PLC – Interim results September 23, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces its unaudited interim results for the six months ended 30 June 2025 (“H1 2025”). Financial summary • Revenue of £24.2 million (H1 2024: £35.6 million), in line with expectations of £47 million for the full year · Includes £5.2 million and £0.3 million revenue contribution from CRS and Cryostore respectively • EBITDA (pre-exceptionals*) of…

#HVO hVIVO PLC – Trading Update and Acquisition January 29, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist early-stage drug development contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, provides an unaudited trading update for the year ended 31 December 2024. Highlights · Revenue up 11.9% to £62.7 million (2023: £56.0 million) · EBITDA margin of c.26% (2023: 23.3%) · Cash of £44.2 million as at 31 December 2024 (31 December 2023: £37.0 million)…

1
2
3
4
Next
Last »